SAN DIEGO, Jan. 19, 2011 /PRNewswire/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly
Update Conference Call for the fourth quarter and full year 2010 on
Wednesday, January 26, 2011 at
5:00 p.m. ET/2:00 p.m. PT. Daniel M.
Bradbury, Amylin's president and chief executive officer,
will lead the call. On the same date post-market, Amylin will
release financial results for the fourth quarter and year ended
December 31, 2010.
The call will be webcast live through the "Investor's" section
of Amylin's corporate website and a recording will be made
available following the close of the call. To access the webcast,
please log on to www.amylin.com approximately fifteen minutes prior
to the call to register, download and install any necessary audio
software. For those without access to the Internet, the live call
may be accessed by phone by calling (800) 857-5738
(U.S./Canada) or (415) 228-4970
(international), participant passcode number 75593. A replay of the
call will also be available by phone beginning approximately two
hours after the close of the call and can be accessed at (888)
567-0472 (U.S./Canada) or (203)
369-3447 (international).
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated
to improving lives of patients through the discovery, development
and commercialization of innovative medicines. Amylin has developed
and gained approval for two first-in-class medicines for diabetes,
SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further
information on Amylin Pharmaceuticals is available at
www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.